157 related articles for article (PubMed ID: 8816892)
21. Prognostic relevance of carcinoembryonic antigen and estrogen receptor status in breast cancer patients.
Esteban JM; Felder B; Ahn C; Simpson JF; Battifora H; Shively JE
Cancer; 1994 Sep; 74(5):1575-83. PubMed ID: 7914825
[TBL] [Abstract][Full Text] [Related]
22. Prognostic and predictive factors of invasive ductal breast carcinomas.
Lialiaris TS; Georgiou G; Sivridis E; Kareli D; Tripsiannis G; Papageorgiou A; Chrisafi S; Kritsi Z; Giatromanolaki A
J BUON; 2010; 15(1):79-88. PubMed ID: 20414932
[TBL] [Abstract][Full Text] [Related]
23. Tumor thickness and histological features as predictors of invasive foci within preoperatively diagnosed ductal carcinoma in situ.
Mori K; Takeda M; Kodama Y; Kiyokawa H; Yasojima H; Mizutani M; Otani Y; Morikawa N; Masuda N; Mano M
Hum Pathol; 2017 Jun; 64():145-155. PubMed ID: 28434924
[TBL] [Abstract][Full Text] [Related]
24. Clinical relevance of immunohistochemical expression of p53-targeted gene products mdm-2, p21 and bcl-2 in breast carcinoma.
Bánkfalvi A; Tory K; Kemper M; Breukelmann D; Cubick C; Poremba C; Füzesi L; Lellè RJ; Böcker W
Pathol Res Pract; 2000; 196(7):489-501. PubMed ID: 10926327
[TBL] [Abstract][Full Text] [Related]
25. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer.
Thor AD; Berry DA; Budman DR; Muss HB; Kute T; Henderson IC; Barcos M; Cirrincione C; Edgerton S; Allred C; Norton L; Liu ET
J Natl Cancer Inst; 1998 Sep; 90(18):1346-60. PubMed ID: 9747866
[TBL] [Abstract][Full Text] [Related]
26. Clinical implications of CSN6 protein expression and correlation with mutant-type P53 protein in breast cancer.
Wang W; Tang M; Zhang L; Xu X; Qi X; Yang Y; Jin F; Chen B
Jpn J Clin Oncol; 2013 Dec; 43(12):1170-6. PubMed ID: 24106298
[TBL] [Abstract][Full Text] [Related]
27. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers.
Thor AD; Moore DH II; Edgerton SM; Kawasaki ES; Reihsaus E; Lynch HT; Marcus JN; Schwartz L; Chen LC; Mayall BH
J Natl Cancer Inst; 1992 Jun; 84(11):845-55. PubMed ID: 1317462
[TBL] [Abstract][Full Text] [Related]
28. Mitochondrial UCP4 and bcl-2 expression in imprints of breast carcinomas: relationship with DNA ploidy and classical prognostic factors.
Gonidi M; Athanassiadou AM; Patsouris E; Tsipis A; Dimopoulos S; Kyriakidou V; Chelidonis G; Athanassiadou P
Pathol Res Pract; 2011 Jun; 207(6):377-82. PubMed ID: 21621926
[TBL] [Abstract][Full Text] [Related]
29. Relationship between p53 expression and other prognostic factors in human breast carcinoma. An immunohistochemical study.
Martinazzi M; Crivelli F; Zampatti C; Martinazzi S
Am J Clin Pathol; 1993 Sep; 100(3):213-7. PubMed ID: 8379528
[TBL] [Abstract][Full Text] [Related]
30. Histologic grade and p53 immunoreaction as indicators of early recurrence of node-negative breast cancer.
Iwaya K; Tsuda H; Fukutomi T; Tsugane S; Suzuki M; Hirohashi S
Jpn J Clin Oncol; 1997 Feb; 27(1):6-12. PubMed ID: 9070333
[TBL] [Abstract][Full Text] [Related]
31. p53 mutations and histological type of invasive breast carcinoma.
Marchetti A; Buttitta F; Pellegrini S; Campani D; Diella F; Cecchetti D; Callahan R; Bistocchi M
Cancer Res; 1993 Oct; 53(19):4665-9. PubMed ID: 8402644
[TBL] [Abstract][Full Text] [Related]
32. Breast carcinoma in women under the age of 50: Relationship between p53 immunostaining, tumour grade, and axillary lymph node status.
Pratap R; Shousha S
Breast Cancer Res Treat; 1998 May; 49(1):35-9. PubMed ID: 9694609
[TBL] [Abstract][Full Text] [Related]
33. P53 in breast carcinomas: association between presence of mutation and immunohistochemical expression using a semiquantitative approach.
Schmitt FC; Soares R; Cirnes L; Seruca R
Pathol Res Pract; 1998; 194(12):815-9. PubMed ID: 9894246
[TBL] [Abstract][Full Text] [Related]
34. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma.
Gasparini G; Weidner N; Bevilacqua P; Maluta S; Dalla Palma P; Caffo O; Barbareschi M; Boracchi P; Marubini E; Pozza F
J Clin Oncol; 1994 Mar; 12(3):454-66. PubMed ID: 7509851
[TBL] [Abstract][Full Text] [Related]
35. p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer.
Barbareschi M; Leonardi E; Mauri FA; Serio G; Dalla Palma P
Am J Clin Pathol; 1992 Oct; 98(4):408-18. PubMed ID: 1357956
[TBL] [Abstract][Full Text] [Related]
36. P53, c-erbB-2 expression and steroid hormone receptors in breast carcinoma: correlations with histopathological parameters.
Kilinç N; Yaldiz M
Eur J Gynaecol Oncol; 2004; 25(5):606-10. PubMed ID: 15493177
[TBL] [Abstract][Full Text] [Related]
37. Fibrotic focus in invasive ductal carcinoma of the breast: a histopathological prognostic parameter for tumor recurrence and tumor death within three years after the initial operation.
Hasebe T; Tsuda H; Tsubono Y; Imoto S; Mukai K
Jpn J Cancer Res; 1997 Jun; 88(6):590-9. PubMed ID: 9263537
[TBL] [Abstract][Full Text] [Related]
38. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.
Korkolopoulou P; Christodoulou P; Kapralos P; Exarchakos M; Bisbiroula A; Hadjiyannakis M; Georgountzos C; Thomas-Tsagli E
Pathol Res Pract; 1997; 193(11-12):767-75. PubMed ID: 9521509
[TBL] [Abstract][Full Text] [Related]
39. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
40. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.
Azizun-Nisa ; Bhurgri Y; Raza F; Kayani N
Asian Pac J Cancer Prev; 2008; 9(4):553-6. PubMed ID: 19256737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
